Meta-analysis quantifies Lecanemab’s efficacy on cognitive outcomes in Alzheimer’s disease, indicating its potential benefits and safety concerns.
This meta-analysis aims to synthesize evidence from clinical trials to quantify Lecanemab’s efficacy on key cognitive, functional, and biomarker outcomes, and to determine the pooled incidence of its primary safety concerns, ARIA-E and ARIA-H.
No takes yet. Share an insight, caveat, or question.
Leite et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: